SIH Partners’s Ionis Pharmaceuticals IONS Stock Holding History

SIH Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,999	Closed	-$362K	–	244
2025 Q1	$362K	Buy	+11,999	New	+$393K	0.01%	180

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SIH Partners's IONS Position: Q2 2025 in Review

SIH Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2025, closing a stake of 11,999 shares — an estimated $362K sold.

SIH Partners first reported a position in IONS in Q1 2025 and held it in 1 quarter. The position peaked at $362K in Q1 2025. 362 funds tracked by Wall St. Rank hold IONS as of Q2 2025.

SIH Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
SIH Partners sold 11,999 Ionis Pharmaceuticals shares in Q2 2025, an estimated $362K.
SIH Partners first reported a position in Ionis Pharmaceuticals in Q1 2025 and held it in 1 quarter.
SIH Partners's Ionis Pharmaceuticals position peaked at $362K in Q1 2025.
362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2025.

Based on SIH Partners's 13F filing for Q2 2025, filed 14 Aug 2025.